The Indian Supreme Court’s refusal to uphold the patent on Gleevec, the blockbuster cancer drug developed by the Swiss pharmaceutical giant Novartis, is good news for many of those in India suffering from cancer. If other developing countries follow India’s example, it will be good news elsewhere, too
Not AvailableThe Indian pharmaceutical sector is large and has the potential of a global leader for...
Access to medicines has re-emerged as a global issue in the wake of COVID-19. India stands out as a ...
The Delhi High Court has rejected the petition filed by Bayer Corporation seeking to stop the Drugs ...
Abstract Background Glivec (imatinib mesylate), produ...
The Swiss drug company Novartis challenged India\u27s status as the Pharmacy of the Developing Worl...
Before eying on such a most awaited Supreme Court ruling (in Novartis case), I wish to refresh a new...
Through the Patents (Amendment) Act of 2005, the Indian Parliament revised the Patents Act of 1970 t...
Writing in Science, LSE’s Kenneth Shadlen, Bhaven Sampat (Columbia) and Tahir Amin (Harvard) debate ...
Not many constitutional decisions from developing countries find themselves at the center of global ...
The Indian lower and upper parliaments have passed a controversial bill that threatens worldwide acc...
LSE’s Kenneth Shadlen asks whether a recent Indian Supreme Court decision on pharmaceutical patents ...
An Indian Supreme Court decision about variants of existing compounds could affect access to afforda...
In the pharmaceutical context, many Southern African Development Community (SADC) members grant pate...
The ever-greening of pharmaceutical patents is a contentious issue relating to intellectual property...
More than 2,600 people reportedly died during clinical trials for new drugs in India between 2005 an...
Not AvailableThe Indian pharmaceutical sector is large and has the potential of a global leader for...
Access to medicines has re-emerged as a global issue in the wake of COVID-19. India stands out as a ...
The Delhi High Court has rejected the petition filed by Bayer Corporation seeking to stop the Drugs ...
Abstract Background Glivec (imatinib mesylate), produ...
The Swiss drug company Novartis challenged India\u27s status as the Pharmacy of the Developing Worl...
Before eying on such a most awaited Supreme Court ruling (in Novartis case), I wish to refresh a new...
Through the Patents (Amendment) Act of 2005, the Indian Parliament revised the Patents Act of 1970 t...
Writing in Science, LSE’s Kenneth Shadlen, Bhaven Sampat (Columbia) and Tahir Amin (Harvard) debate ...
Not many constitutional decisions from developing countries find themselves at the center of global ...
The Indian lower and upper parliaments have passed a controversial bill that threatens worldwide acc...
LSE’s Kenneth Shadlen asks whether a recent Indian Supreme Court decision on pharmaceutical patents ...
An Indian Supreme Court decision about variants of existing compounds could affect access to afforda...
In the pharmaceutical context, many Southern African Development Community (SADC) members grant pate...
The ever-greening of pharmaceutical patents is a contentious issue relating to intellectual property...
More than 2,600 people reportedly died during clinical trials for new drugs in India between 2005 an...
Not AvailableThe Indian pharmaceutical sector is large and has the potential of a global leader for...
Access to medicines has re-emerged as a global issue in the wake of COVID-19. India stands out as a ...
The Delhi High Court has rejected the petition filed by Bayer Corporation seeking to stop the Drugs ...